Oric Pharmaceuticals
ORIC
90 hedge funds and large institutions have $291M invested in Oric Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 28 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
8% more funds holding
Funds holding: 83 → 90 (+7)
4% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 28
12.87% less ownership
Funds ownership: 100.99% → 88.12% (-13%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
18% less capital invested
Capital invested by funds: $353M → $291M (-$62.7M)
24% less call options, than puts
Call options by funds: $216K | Put options by funds: $285K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.48M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.49M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$6.37M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$6M |
| 5 |
Alkeon Capital Management
New York
|
+$4.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.92M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$3.83M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.68M |
| 4 |
O
OrbiMed
New York
|
-$2.25M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$1.49M |
ORIC Hedge Fund Activity: Q3 2023 in Review
90 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q3 2023, worth a combined $291M — down 18% from $353M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ORIC positions and 9 closed out — a net gain of 7 holders — while 27 added to existing stakes and 28 trimmed.
The largest buyer was BlackRock, adding an estimated $9.48M. The largest seller was Fidelity Investments, cutting an estimated $4.92M.
- 90 institutional investors held Oric Pharmaceuticals (ORIC) as of Q3 2023, up from 83 in Q2 2023.
- Funds reported $291M of Oric Pharmaceuticals stock for Q3 2023, down 18% quarter-over-quarter.
- 16 funds opened new Oric Pharmaceuticals positions in Q3 2023 and 9 closed out, a net change of +7 holders.
- The largest Oric Pharmaceuticals buyer in Q3 2023 was BlackRock, an estimated $9.48M added.
- The largest Oric Pharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $4.92M sold.
Based on aggregated 13F filings for Q3 2023.